what is gip glp 1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Frontiers | Mechanisms of action

Understanding GLP-1 Agonist Drugs GLP-1 agonist drugs, such as Ozempic (semaglutide) and Mounjaro (dulaglutide), are commonly prescribed to help manage type 2 diabetes

[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Rhee S.Y., Han K.D., Kwan H., Park S.E., Park Y.G., Kim Y.H., Yoo S.J., Rhee E.J., Lee W.Y

The three year absolute risk was 2.4% (95% CI 2.1% to 2.7%) lower for SGLT-2 inhibitors than DPP-4 inhibitors (4.6% v 7.0%), 1.8% (1.4% to 2.1%) lower for GLP-1 receptor agonists than DPP-4 inhibitors (5.7% v 7.5%), and 1.2% (0.9% to 1.5%) lower for SGLT-2 inhibitors than GLP-1 receptor agonists (4.7% v 6.0%)

GLP-1 receptor agonists may provide additional cardiovascular and renal benefits in selected patients

Contrary to GLP-1R mono-agonist, whose efficacy is limited by dose-dependent gastrointestinal events, the new triple agonists can simultaneously increase energy expenditure, reduce food intake, and improve glucose control by engaging all three receptors at once

Obesity and Sexual Functioning